drugset / Trial / NCT04403776
PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
RandomizedCrossoverOpen-labelOther
Summary
A study to characterize the single-dose and steady-state pharmacokinetics of tofacitinib Modified Release (MR) formulation as well as to compare the extent of absorption of the MR 11 mg formulation (once daily) to that of the Immediate Release (IR) 5 mg formulation (twice daily) of tofacitinib in Chinese healthy subjects under fasted conditions.
Timeline
- Start
- 2018-12-03
- Primary completion
- 2019-02-12
- Completion
- 2019-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |
| Subject | Tofacitinib | Small molecule | 11 mg | Oral |
Indications
No indication recorded.